2024
Cellular therapeutics and immunotherapies in wound healing – on the pulse of time?
Huelsboemer L, Knoedler L, Kochen A, Yu C, Hosseini H, Hollmann K, Choi A, Stögner V, Knoedler S, Hsia H, Pomahac B, Kauke-Navarro M. Cellular therapeutics and immunotherapies in wound healing – on the pulse of time? Military Medical Research 2024, 11: 23. PMID: 38637905, PMCID: PMC11025282, DOI: 10.1186/s40779-024-00528-5.Peer-Reviewed Original ResearchConceptsStandard of careChronic wound healing disordersLocal wound irrigationWound healingChronic inflammatory microenvironmentFree flap techniqueWound healing disordersChronic woundsGenetic risk profilesPhysiological wound healingAdequate blood supplySurgical debridementFlap techniqueCellular therapyCurrent therapiesHealing disordersInflammatory microenvironmentWound irrigationNon-healing woundsCellular therapeuticsGeneral anesthesiaFormation of biofilmsWound debridementSkin graftsImmunotherapyImmune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions
Knoedler L, Dean J, Diatta F, Thompson N, Knoedler S, Rhys R, Sherwani K, Ettl T, Mayer S, Falkner F, Kilian K, Panayi A, Iske J, Safi A, Tullius S, Haykal S, Pomahac B, Kauke-Navarro M. Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions. Frontiers In Immunology 2024, 15: 1372862. PMID: 38650942, PMCID: PMC11033354, DOI: 10.3389/fimmu.2024.1372862.Peer-Reviewed Original ResearchConceptsRegulatory myeloid cellsSolid organ transplantationVascularized composite allotransplantationMesenchymal stromal cellsT cellsTransplant patientsCellular therapyChimeric antigen receptor T cellsTransplant surgerySide effectsIncreased risk of malignancyProgression to chronic rejectionAcute rejection ratesPerioperative treatment strategiesRegulatory T cellsPromote immune toleranceRisk of malignancySystemic side effectsRelated side effectsCell typesImprove transplant survivalCAR-TCell therapy applicationsImmunosuppressive regimensChronic rejection
2022
mTORC1 Inhibition Protects Human Regulatory T Cells From Granzyme-B-Induced Apoptosis
Eskandari SK, Allos H, Al Dulaijan B, Melhem G, Sulkaj I, Alhaddad JB, Saad AJ, Deban C, Chu P, Choi JY, Kollar B, Pomahac B, Riella LV, Berger SP, Sanders JSF, Lieberman J, Li L, Azzi JR. mTORC1 Inhibition Protects Human Regulatory T Cells From Granzyme-B-Induced Apoptosis. Frontiers In Immunology 2022, 13: 899975. PMID: 35757726, PMCID: PMC9229986, DOI: 10.3389/fimmu.2022.899975.Peer-Reviewed Original ResearchConceptsRegulatory T cellsT cellsHuman regulatory T cellsHost THumanized mouse modelPro-apoptotic pathwaysSkin allotransplantationClinical efficacyImmunosuppressive potencyIntracytoplasmic expressionTransplant fieldMouse modelCellular therapyHigh expressionTarget cellsRapamycin complex 1Lysosomal granulesFunctional effectsMechanistic targetPatientsApoptosisC-JunGranzymesDrug targetsS6K
2013
Vascularized composite tissue allotransplantation – state of the art
Diaz‐Siso J, Bueno E, Sisk G, Marty F, Pomahac B, Tullius S. Vascularized composite tissue allotransplantation – state of the art. Clinical Transplantation 2013, 27: 330-337. PMID: 23581799, PMCID: PMC3724233, DOI: 10.1111/ctr.12117.Peer-Reviewed Original ResearchConceptsImmunosuppression-related side effectsVascularized composite tissue allotransplantationLong-term graft lossEarly post-operative periodChronic graft deteriorationPost-operative periodLong-term outcomesViable treatment optionConventional reconstructive techniquesComposite tissue allotransplantationAcute rejectionGraft lossGraft deteriorationTolerance inductionTreatment optionsLifelong immunosuppressionLower extremitiesImmune responseAnatomic locationReconstructive techniquesAbdominal wallSide effectsTissue allotransplantationFunctional restorationCellular therapy